Respiratorius investor relations material

Respiratorius AB develops drug candidates with the goal of launching or out-licensing drugs for the treatment of aggressive lymphoma (cancer). Respiratorius is developing a new drug as a pretreatment to enhance the effects of the standard treatment currently used for the treatment of diffuse large B-cell lymphoma, the most common type of aggressive lymphoma.